Barclays Remains a Hold on Zoetis Inc. (ZTS)

Core Insights - Zoetis Inc. (NYSE:ZTS) is recognized as a strong investment option in the pet stock sector, with a Hold rating reaffirmed by Barclays and a price target set at $136.00 [1] - The company reported fiscal Q4 2025 revenue of $2.4 billion, marking a 3% increase from fiscal Q4 2024, with net income reaching $603 million, or $1.37 per diluted share, reflecting increases of 4% and 6% respectively [1] - For the full year 2025, Zoetis reported total revenue of $9.5 billion, a 2% growth compared to 2024, with net income of $2.7 billion, or $6.02 per diluted share, showing increases of 8% and 10% respectively [2] Company Overview - Zoetis Inc. is a global leader in animal health, focusing on the development and commercialization of vaccines, medicines, and diagnostic products [3] - The company's operations are segmented into the United States and International markets, offering a diverse product portfolio that includes vaccines, parasiticides, and animal health diagnostics [3] - Zoetis specializes in products for eight core species, including companion animals (dogs, cats, horses), cattle, swine, livestock (sheep, fish), and poultry [3]